37 results about "Uridine monophosphate" patented technology

The invention discloses a weaned piglet nucleotide feed additive. The weaned piglet nucleotide feed additive comprises, by weight, 0.8 to 1.3 of adenosine monophosphate 5'-AMP, 0.3 to 0.8 of cytidine monophosphate 5'-CMP, 1.1 to 1.5 of guanosine monophosphate 5'-GMP and 0.7 to 1.4 of uridine monophosphate 5'UMP. The invention further discloses a preparation method and an application of the feed additive. According to the weaned piglet nucleotide feed additive, stress reaction of weaned piglets can be effectively relieved, the piglet grazing rate and the feed utilization efficiency are improved, the oxidation resistance and the immune function of weaned piglets are improved apparently, the organic resistance is enhanced, and accordingly, important significances are provided for modern scientific, intensive and large-scale pig production.

The invention discloses a method for increasing pulullan yield by sub-sectional adding of growth factors in a fermentation process, and belongs to the technical field of biological fermentation engineering. The method comprises the following steps: producing pulullan from aureobasidium pullulans CGMCC NO.7055 in a fermentation manner; adding 0.003-0.005% of vitamin B1 when bacteria growth is at the beginning of the logarithmic phase; and adding 0.002-0.004% of uridine monophosphate when the bacteria growth is at the early stage of a stable stage, so as to induce and facilitate accumulation of secondary metabolite, namely the pulullan. The growth factors are specifically added according to the characteristics of sugar production in different growth periods and fermentation processes, so that the method is convenient and fast to operate and has an obvious effect; the fermentation period is greatly shortened, the transformation rate of a substrate is increased, and the cost of the pulullan is reduced.

The invention discloses a preparing method of uridine diphosphite, which comprises the following steps: blending uridine monophosphate and beer yeast to ferment; terminating fermenting to obtain the ferment liquid of uridine triphosphate; predisposing ferment liquid; separating and purifying; proceeding acid heat to decompose purified uridine triphosphate; filtering; separating; refining. The invention shortens the predisposing time by two thirds and separating purifying time by one third, which makes receiving rate by over 30%.

The invention discloses a nucleotide probiotic capsule for delaying senescence, and belongs to the technical field of medicine and health care. The nucleotide probiotic capsule comprises a capsule shell and a content, wherein the content comprises four exogenous nucleotides and five probiotics; the exogenous nucleotides comprise 5'-cytidine monophosphate (5'-CMP), 5'-adenosine monophosphate (5'-AMP), 5'-disodium uridine monophosphate (5'-UMPNa2) and 5'-disodium guanylate (5'-GMPNa2); the probiotics comprise lactobacillus acidophilus, lactobacillus plantarum, lactobacillus casei and the like; and the content of the probiotics is greater than 1 * 10 <7>CFU/g. The nucleotide probiotic capsule for delaying senescence can remove free radicals in a body, inhibit oxidative damage of the free radicals to the body and prolong the cell life, has multiple health care effects of delaying senescence, prolonging life, improving immunity, regulating intestinal flora and the like, is convenient to carry and take, and is a health care food suitable for middle-aged and elderly people.

Medical dairy products are highly concentrated in proteins and minerals. Formulation of such products is challenging, since viscosities can easily increase during processing and storage. It was found that using one or more chelating agents selected from the group consisting of a phosphoric acid, citric acid, a soluble phosphate salt, a soluble citrate salt, or a mixture thereof, the viscosity and the transparency of an aqueous micellar casein composition, comprising 6 to 20 g/100 ml of micellar casein and having a pH of about 6 to 8 could be controlled independently of each other. It was found that products become more viscous after addition of phytate, citrate, or orthophosphate, and that the viscosity depends on concentration and type of phosphate. Addition of hexametaphosphate leads to gel formation. In contrast, high concentrations of uridine monophosphate can be added without significantly affecting the viscosity.

The invention provides a better and suitable simplified representative unicellular whole-genome database creating method and application thereof. On one hand, the method can be effectively applied totrace samples or samples with smaller cell population to perform simplified genome database creation by optimizing primers and amplifying steps; on the other hand, by means of enzyme correction treatment, an enzyme treating step capable of specifically resecting uridine monophosphate can be applied to a simplified genome unicellular sample amplifying method, and amplification error rate can be remarkably reduced. Compared with the prior art, the method creatively applies an optimized and improved unicellular database creating scheme to simplified genome database creation of the trace samples or the samples with the smaller cell population; meanwhile, compared with the prior art, the method has the advantages of higher efficiency, simpleness, practicability, accuracy, small loss, low cost,good method repeatability, low error rate, great suitability for the simplified genome unicellular whole-genome amplification of the trace samples or the samples with the smaller cell population and ability in widening sample application ranges; meanwhile, the error rate is reduced, and detection accuracy is improved.

The invention discloses a preparation method of phosphate ester, and relates to the technical field of pharmaceutical chemicals. Uridine monophosphate or salt thereof and a pyrophosphoric acid activecompound are used, and under the action of a metal ion catalyst Ca<2+>, Mn<2+> or Mg<2+>, high-purity U2P4 can be obtained with high yield in large-scale industrial production.

The invention discloses a primer composition for detecting a harmful gene of deficiency of uridine monophosphate synthase of cattle, a kit with the primer composition and an application of the kit. The primer composition disclosed by the invention is composed of a primer group A and a primer group B, wherein the primer group A is composed of a primer 1 and a primer 2, the primer group B is composed of a primer 3 and a primer 4, and the nucleotide sequences of the primer 1, the primer 2, the primer 3 and the primer 4 are respectively shown as SEQIDNO. 1-4. The invention also provides the kit with the primer composition. The method for applying the kit disclosed by the invention to the detection of the harmful gene of the deficiency of uridine monophosphate synthase of cattle comprises the steps of extracting the complete set of DNA (Deoxyribonucleic acid) in cattle blood as a template to carry out nested PCR (Polymerase Chain Reaction) amplification to obtain a PCR product, and sequencing the obtained PCR product so as to directly know about the basic group change on a mutation site according to a sequenced result, thereby ensuring the accuracy of the result and meeting the requirements of a detecting technology for characteristics such as high speed, precision, high throughput and the like.

The invention discloses a metabonomics-based chilled fresh meat freshness marker and a screening and prediction model fitting method and application thereof. The marker is prepared from indole-3-formaldehyde, uridine monophosphate, phenylmercaptouric acid, gluconic acid, tyramine and serine-phenylalanine. The prediction model is: Y=3.964+1.97E<-7>X1- 4.22E<-7>X2-3.37E<-7>X3+8.80E<-8>X4+1.26E<-8>X5-5.57E<-7>X6. According to the method, an Agilent 1290 UHPLC is connected with a Q Exactive Orbitrap high-resolution mass spectrum in series, the method has higher resolution, more substances can be detected more accurately, metabolites in the preservation process of the chilled fresh chicken can be illustrated more comprehensively, and the obtained result is more reliable.

The invention provides a recombinant microorganism for producing uridine and a method for producing uridine by using the recombinant microorganism. Wherein the uridine is degraded and knocked out by using genes, and the genes encode ribonucleoside hydrolase, uridine phosphorylase, nucleoside phosphorylase, cytidine/uridine kinase and nucleoside transporter protein. Meanwhile, overexpression is carried out on key enzymes in a uridine biosynthetic pathway, including cytidine triphosphate pyrophosphorylase for degrading cytidine triphosphate to cytidine monophosphate and uridine monophosphate phosphorylase for catalyzing uridine monophosphate to uridine. In addition, a pyrimidine nucleoside pathway is subjected to genetic engineering modification, and feedback inhibition of a synthetic pathway is relieved. The recombinant strain can reach the uridine yield of 20 g/L or above in a 5-liter fermentation tank through a biological fermentation method, industrial mass production can be achieved, meanwhile, the uridine production cost is low, pollution is reduced, the method is green and environmentally friendly, and the method has high application and popularization value.

The invention relates to the field of molecular biology and provides an Oligo dT primer. The Oligo dT primer contains single-chain DNA molecules having a continuous dT sequence, wherein the DNA molecules contain recognition sites used for cutting; and the recognition sites used for cutting refer to uridine monophosphate, deoxyinosine or phosphorothioate bond. The invention also provides a method for constructing a cDNA library on the basis of the Oligo dT primer. The Oligo dT primer disclosed by the invention is high in applicability and can be applied to multiple different library construction schemes; the initiation sites at the polyA tails of mRNA molecules can be accurately positioned; and according to the method for constructing the cDNA library disclosed by the invention, all the mRNA molecules in samples can be specifically reflected in the constructed cDNA library.

The invention relates to a compound nucleotide immunoenhancer for paralichthys olivaceus, which is composed of the following substances in percentage by weight: 55-65% of cytidylate, 5-15% of uridine monophosphate, 5-15% of thymidine phosphorylase, 1-5% of hypoxanthine nucleotide and 10-20% of bioactive peptide. The compound nucleotide immunoenhancer disclosed by the invention is capable of obviously improving the ingestion and the growth of paralichthys olivaceus, and remarkably improving the cellular immunity, the humoral immunity, the immune gene expression quantity, the disease resistance and the like of paralichthys olivaceus. Moreover, the compound nucleotide immunoenhancer can also be directly added in a feed for paralichthys olivaceus, and orally fed; and the compound nucleotide immunoenhancer has the advantages of being free from toxic and side residues, free from drug resistance, and pollution-free to environment.

The invention discloses a method for producing uridine diphosphate glucose and special engineering bacteria for the method. The method for producing the uridine diphosphate glucose comprises the following steps of by using uridine monophosphate and sucrose as raw materials, producing the uridine diphosphate glucose under the action of the engineering bacteria, wherein the engineering bacteria arerecombinant bacteria for expressing functional protein and are obtained by introducing a gene for encoding the functional protein into starting bacteria, and the functional protein comprises polyphosphokinase, uridine monophosphate kinase and sucrose synthase. The method is of great significance to industrial production of the uridine diphosphate glucose.

The invention relates to a preparation method of P<1>,P<4>-di(uridine 5'-)tetraphosphate. The method comprises the following steps: under the action of a metal salt catalyst, imidazole triethylamine pyrophosphate shown in formula I and uridine monophosphate triethylamine salt shown in formula II react in N,N-dimethylformamide, and P<1>,P<4>-di(uridine 5'-)tetraphosphate shown in formula III is obtained.

The invention is about a method of measuring the activation of 5í»-phosphonuclease, and it also concerns the reagent box of 5í»-phosphonucleasediagnosis. This invention belongs to the field of medical testing and measuring technology. The reagent box is consisted of buffer solution, uridine monophosphate, reduced coenzyme, uridine phosphorylase, dihydrothymine dehyddrogenase and stabilizer. Firstly, we cause an enzyme-coupled reaction through mixing the sample and the reagent according to a certain proportion of volume; secondly, put the final reactant under the biochemical analyzer and test the absorbance variational situation (speed) of dominant wavelength; then we can get theactivation of 5í»-phosphonuclease. By using this invention, we can get the necessary measuring result with high sensitiveness and fine precision through biochemical analyzer, and the result would not be contaminated by material of internal and exogenous sources. Thus, this method can be conveniently promoted and applied.

The invention discloses a fluorescence labeling-based uridine monophosphate acidification detection method. The method comprises the following steps of: adding YdiU protein and a substrate into a reaction system, mixing the substances uniformly, then adding 1 microliter of CY3-X-UTP, and carrying out UMPylation modification reaction at 30-40DEG C for 1h to obtain UMPylation modified protein with aCY3 label; after adding the UMPylation modified protein into a sample loading buffer solution, using 12% SDS-PAGE gel electrophoresis; and carrying out fluorescence imaging on the buffer solution, and carrying out imaging observation under 565nm emission after 553nm excitation. The method is used for qualitatively identifying the protein possibly subjected to uridine monophosphate modification, can determine a specific modification site by combining mass spectrometry, and can be used for screening an inhibitor of targeted uridine monophosphate transferase.

The invention is about a method of measuring the activation of 5í»-phosphonuclease, and it also concerns the reagent box of 5í»-phosphonucleasediagnosis. This invention belongs to the field of medical testing and measuring technology. The reagent box is consisted of buffer solution, uridine monophosphate, oxidized coenzyme, uridine nucleotide, ribose1-dehyddrogenase and stabilizer. Firstly, we cause an enzyme-coupled reaction through mixing the sample and the reagent according to a certain proportion of volume; secondly, put the final reactant under the biochemical analyzer and test the absorbance variational situation (speed) of dominant wavelength; then we can get the activation of 5í»-phosphonuclease. By using this invention, we can get the necessary measuring result with high sensitiveness and fine precision through biochemical analyzer, and the result would not be contaminated by material of internal and exogenous sources. Thus, this method can be conveniently promoted and applied.